Keymed Biosciences Inc. debuted on the Hong Kong Stock Exchange (HKSE) on July 8, raising HK$2.94 billion (US$378.48 million) in the process. The company will use the funds raised for the R&D and commercialization of key pipeline candidates.
LONDON – The World Health Organization (WHO) is to set up a channel for confidential reporting of illegal, unregistered, unethical or unsafe human genome editing research, as part of a new governance framework it is proposing to develop.
In infectious disease research, most of the research into genetic determinants of susceptibility to infection and disease severity are focused on the host. For COVID-19, for example, the delta variant’s infectivity, and how likely infection is to lead to severe disease, is the focus of an intense research agenda. But host genetics, too, contribute to the consequences of infections. An ongoing study into the host genetics of SARS-CoV-2 infection has identified 13 such factors that affected either the likelihood of contracting SARS-CoV-2, or the severity of disease, gleaned from the data of 50,000 infected persons and 2 million controls.
PERTH, Australia – Amaroq Therapeutics Ltd., a spinout out of the University of Otago in Dunedin, New Zealand, has launched after securing NZ$14 million (US$9.7 million) in seed funding to develop long non-coding RNAs to treat breast, colorectal and liver cancer.
I-Mab Biopharma Co. Ltd. announced collaborations with mRNA biotech company Immorna (Hangzhou) Biotechnology Co. Ltd. and AI-enabled R&D company Neox Biotech Co. Ltd., gaining access to transformative technologies to discover and develop oncology therapeutics.
Fresh from showcasing preliminary evidence for the tolerability and potential benefits of LVGN-6051 at ASCO’s annual meeting in June, Lyvgen Biopharma Holdings Co. Ltd. is gearing up to move its CD40 agonist LVGN-7409 to clinical trials in China after initial U.S. patient dosing.
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Beigene, Hangzhou Chance, Humanigen, Immutep, Innovent, Janssen-Cilag International, Moderna, Opthea, Recipharm, Replicel Life Sciences, Sciclone, Y-Mabs, Zydus Cadila.
In a deal that could be worth up to $937.5 million, Biogen Inc. licensed rights to phase II-stage, brain-penetrant BTK inhibitor orelabrutinib from Innocare Pharma Ltd. for the treatment of multiple sclerosis (MS) and autoimmune diseases. It’s the first mega out-licensing deal for the Chinese firm, which will receive $125 million up front and is eligible to receive up to $812.5 million in potential development milestones and commercial payments, plus tiered royalties in the low to high teens on potential future net sales.
Brii Biosciences Ltd. raised HK$2.482 billion (US$319 million) in its IPO in Hong Kong and will use the proceeds to support the development of its key assets, which includes programs for hepatitis B virus (HBV), HIV and drug-resistant infections.
RSS
